Dermatology, Nasal Sprays Among Emerging OTC Switch Categories
This article was originally published in The Pink Sheet Daily
FDA threw the switch floodgates open with the NSURE initiative and it has fueled interest with the recent first-in-class switches of Nasacort and Oxytrol for Women. Likely categories for successful switches include dermatology, nasal sprays in allergy, sleep, migraine relief and cholesterol management.
You may also be interested in...
Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion by acquiring Stiefel Laboratories and creating a global specialist business across Rx and OTC drugs
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.